Navamedic ASA acquires Impolin AB and bolsters its product portfolio
· The proposed acquisition reinforces Navamedic’s position in the market for obesity treatment · The acquired portfolio enables Navamedic to support patients and consumers during weight loss or obesity treatment · This agreement supports Navamedic’s ambition to become a leading Nordic provider of specialized, high-quality products to hospitals and pharmacies Oslo, 5 May 2022 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, and Impolin AB (Impolin), a Swedish-based, independent distributor of products